Corium Announces Streamlined Bioequivalence Development Path for Transdermal Corplex^TM Memantine
Second Alzheimer’s Candidate to Follow Shortened Clinical Timeline…

Corium Reports Third Quarter Fiscal 2016 Finan ial Results and Recent Corporate Highlights
MENLO PARK, Calif. , Aug. 04, 2016 (GLOBE NEWSWIRE) — Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results for the third…